.Nature Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a mean consequence of 11 months, clients along with metastatic intestinal growths who obtained biomarker-matched treatments based on circulating lump DNA profiling presented a more significant medical benefit than those getting incomparable treatment.